Skip to main content

Advertisement

SpringerLink
Log in

Importance of Absent Neoplastic Epithelium in Patients Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

  • Colorectal Cancer
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

The importance of absent neoplastic epithelium in specimens from cytoreductive surgery (CRS) is unknown. This study aimed to investigate the prevalence and prognostic value of histopathology without neoplastic epithelium in patients treated with CRS and hyperthermic intraperitoneal chemotherapy (HIPEC).

Methods

Data were extracted from medical records and histopathology reports for patients treated with initial CRS and HIPEC at Uppsala University Hospital, Sweden, between 2004 and 2012. Patients with inoperable disease and patients undergoing palliative non-CRS surgery were excluded from the study. Patients lacking neoplastic epithelium in surgical specimens from CRS, with or without mucin, were classified as “neoplastic epithelium absent” (NEA), and patients with neoplastic epithelium were classified as “neoplastic epithelium present” (NEP).

Results

The study observed NEA in 78 of 353 patients (22 %). Mucin was found in 28 of the patients with NEA. For low-grade appendiceal mucinous neoplasms and adenomas, the 5-year overall survival rate was 100 % for NEA and 84 % for NEP, and the 5-year recurrence-free survival rate was 100 % for NEA and 59 % for NEP. For appendiceal/colorectal adenocarcinomas (including tumors of the small intestine), the 5-year overall survival rate was 61 % for NEA and 38 % for NEP, and the 5-year recurrence-free survival rate was 60 % for NEA and 14 % for NEP. Carcinoembryonic antigen level, peritoneal cancer index, and completeness of the cytoreduction score were lower in patients with NEA.

Conclusions

A substantial proportion of patients undergoing CRS and HIPEC have NEA. These patients have a favorable prognosis and a decreased risk of recurrence. Differences in patient selection can affect the proportion of NEA and hence explain differences in survival rates between reported series.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Glehen O, Gilly FN, Boutitie F, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1290 patients. Cancer. 2010;116:5608–18.

    Article  PubMed  Google Scholar 

  2. Bakrin N, Classe JM, Pomel C, Gouy S, Chene G, Glehen O. Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. J Visc Surg. 2014;151:347–53.

    Article  CAS  PubMed  Google Scholar 

  3. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7:69–76.

    Article  PubMed  Google Scholar 

  4. Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449–56.

    Article  PubMed  Google Scholar 

  5. Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007;18:827–34.

    Article  CAS  PubMed  Google Scholar 

  6. Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Ann Surg Oncol. 2007;14:128–33.

    Article  CAS  PubMed  Google Scholar 

  7. Sugarbaker PH, Ryan DP. Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? Lancet Oncol. 2012;13:e362–9.

    Article  PubMed  Google Scholar 

  8. Arjona-Sanchez A, Medina-Fernandez FJ, Munoz-Casares FC, Casado-Adam A, Sanchez-Hidalgo JM, Rufian-Pena S. Peritoneal metastases of colorectal origin treated by cytoreduction and HIPEC: an overview. World J Gastrointest Oncol. 2014;6:407–12.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg. 2009;249:900–7.

    Article  PubMed  Google Scholar 

  10. Sugarbaker PH, Bijelic L, Chang D, Yoo D. Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. J Surg Oncol. 2010;102:576–81.

    Article  PubMed  Google Scholar 

  11. Passot G, You B, Boschetti G, et al. Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis. Ann Surg Oncol. 2014;21:2608–14.

    Article  PubMed  Google Scholar 

  12. Carr NJ, McCarthy WF, Sobin LH. Epithelial noncarcinoid tumors and tumor-like lesions of the appendix: a clinicopathologic study of 184 patients with a multivariate analysis of prognostic factors. Cancer. 1995;75:757–68.

    Article  CAS  PubMed  Google Scholar 

  13. Misdraji J, Yantiss RK, Graeme-Cook FM, Balis UJ, Young RH. Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am J Surg Pathol. 2003;27:1089–103.

    Article  PubMed  Google Scholar 

  14. Pai RK, Beck AH, Norton JA, Longacre TA. Appendiceal mucinous neoplasms: clinicopathologic study of 116 cases with analysis of factors predicting recurrence. Am J Surg Pathol. 2009;33:1425–39.

    Article  PubMed  Google Scholar 

  15. Carr NJ, Sobin LH. Tumours of the appendix. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) World Health Organization Classification of Tumours of the Digestive System. 4th ed. IARC, Lyon, 2010.

    Google Scholar 

  16. Yantiss RK, Shia J, Klimstra DS, Hahn HP, Odze RD, Misdraji J. Prognostic significance of localized extra-appendiceal mucin deposition in appendiceal mucinous neoplasms. Am J Surg Pathol. 2009;33:248–55.

    Article  PubMed  Google Scholar 

  17. Bosman FT, Carneiro F, Hruban RH, Theise NDE. World Health Organization Classification of Tumours of the Digestive System. 4th ed. IARC, Lyon, 2010.

    Google Scholar 

  18. Kurman RJ, Carcangiu ML, Herrington CS, Young RH (eds) World Health Organization Classification of Tumours of Female Reproductive Organs. 4th ed. IARC, Lyon, 2014.

    Google Scholar 

  19. Misdraji J. Mucinous epithelial neoplasms of the appendix and pseudomyxoma peritonei. Mod Pathol. 2015;28(Suppl 1):S67–79.

    Article  PubMed  Google Scholar 

  20. Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis: a clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei.” Am J Surg Pathol. 1995;19:1390–408.

    Article  CAS  PubMed  Google Scholar 

  21. Andreasson H, Wanders A, Sun XF, et al. Histopathological classification of pseudomyxoma peritonei and the prognostic importance of PINCH protein. Anticancer Res. 2012;32:1443–8.

    PubMed  Google Scholar 

  22. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Sugarbaker P. Management of Peritoneal Surface Malignancy Using Intraperitoneal Chemotherapy and Cytoreductive Surgery: A Manual for Physicians and Nurses. 3rd ed. The Ludann Company, Grand Rapids, MI, 1998.

    Google Scholar 

  24. Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol 2005;2:3.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.

    Article  CAS  PubMed  Google Scholar 

  26. Taflampas P, Dayal S, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ. Preoperative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal pseudomyxoma peritonei: analysis of 519 patients. Eur J Surg Oncol. 2014;40:515–20.

    Article  CAS  PubMed  Google Scholar 

  27. Cashin PH, Graf W, Nygren P, Mahteme H. Patient selection for cytoreductive surgery in colorectal peritoneal carcinomatosis using serum tumor markers: an observational cohort study. Ann Surg. 2012;256:1078–83.

    Article  PubMed  Google Scholar 

  28. Carr NJ, Finch J, Ilesley IC, et al. Pathology and prognosis in pseudomyxoma peritonei: a review of 274 cases. J Clin Pathol. 2012;65:919–23.

    Article  PubMed  Google Scholar 

  29. McDonald JR, O’Dwyer ST, Rout S, et al. Classification of and cytoreductive surgery for low-grade appendiceal mucinous neoplasms. Br J Surg. 2012;99:987–92.

    Article  CAS  PubMed  Google Scholar 

  30. Sugarbaker PH. Update on the prevention of local recurrence and peritoneal metastases in patients with colorectal cancer. World J Gastroenterol. 2014;20:9286–91.

    PubMed  PubMed Central  Google Scholar 

  31. Sammartino P, Sibio S, Biacchi D, et al. Prevention of peritoneal metastases from colon cancer in high-risk patients: preliminary results of surgery plus prophylactic HIPEC. Gastroenterol Res Pract. 2012;2012:141585. doi:10.1155/2012/141585.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon’s role. Langenbeck’s Arch Surg. 1999;384:576–87.

    Article  CAS  Google Scholar 

  33. Elias D, Blot F, El Otmany A, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer. 2001;92:71–6.

    Article  CAS  PubMed  Google Scholar 

  34. Tentes AA, Tripsiannis G, Markakidis SK, et al. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol. 2003;29:69–73.

    Article  PubMed  Google Scholar 

  35. Bakrin N, Bereder JM, Decullier E, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013;39:1435–43.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the Swedish Cancer Society, Lions Cancer Research Foundation in Uppsala, Sweden, and grants from Uppsala University Hospital (ALF), Uppsala, Sweden.

Conflict of interest

There are no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Surgical Sciences, Colorectal Surgery, Uppsala University, Uppsala, Sweden

    Malin Enblad MD, Helgi Birgisson MD, PhD, Filip Sköldberg MD, PhD, Lana Ghanipour MD, PhD & Wilhelm Graf MD, PhD

  2. Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden

    Alkwin Wanders MD, PhD

Authors
  1. Malin Enblad MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Helgi Birgisson MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alkwin Wanders MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Filip Sköldberg MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lana Ghanipour MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wilhelm Graf MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Malin Enblad MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Enblad, M., Birgisson, H., Wanders, A. et al. Importance of Absent Neoplastic Epithelium in Patients Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol 23, 1149–1156 (2016). https://doi.org/10.1245/s10434-015-4989-y

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-015-4989-y

Keywords

Search

Navigation